AmberGen, Inc. (AMB) is leading innovator of molecular diagnostics. We are developing clinical assays based on novel molecular profiling technology which can accurately diagnose and predict the course of a variety of diseases.

These tools will allow physicians to more accurately make optimal therapeutic decisions tailored to individual patients. Products include tests to determine the likelihood of relapse from cancer and diagnosis of specific autoimmune diseases.